Physician profile
Jennifer R Smith
NPI 1659822211
$4,624.74
in general payments reported to CMS, 2019-2025
26 companies · $1,133 in 2025
The $1,133 reported for 2025 was more than what 86% of Gerontology (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $161).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,172 · 2022: $1,185 · 2023: $703 · 2024: $431 · 2025: $1,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,267.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,120.96 | 2021-2025 | Aveir, Gallant, Navitor |
| Novartis Pharmaceuticals Corporation | $765.96 | 2021-2025 | |
| Pfizer INC. | $622.18 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $520.40 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $450.50 | 2021-2025 | Wainua, Farxiga |
| Amgen INC. | $164.83 | 2021-2024 | Repatha |
| Abbvie INC. | $154.97 | 2025 | |
| Alnylam Pharmaceuticals INC. | $110.90 | 2022-2025 | Amvuttra, Onpattro |
| E.R. Squibb & Sons, L.L.C. | $106.58 | 2021-2024 | Camzyos |
| Sanofi-Aventis U.S. LLC | $72.71 | 2022-2023 | |
| Inspire Medical Systems, INC. | $62.46 | 2023-2024 | Inspire |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $61.62 | 2023-2024 | Lifevest |
| Cvrx, INC. | $51.37 | 2023-2024 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $51.09 | 2022-2023 | |
| Edwards Lifesciences Corporation | $42.08 | 2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $37.80 | 2024 | Injectafer |
| Novo Nordisk INC | $35.07 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Lexicon Pharmaceuticals, INC. | $31.89 | 2023 | Inpefa |
| Boston Scientific Corporation | $29.47 | 2022 | |
| Esperion Therapeutics, INC. | $28.18 | 2021-2022 | |
| Angiodynamics, INC. | $27.28 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.04 | 2024 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.02 | 2022 | |
| Avinger INC. | $13.19 | 2022 | |
| Amarin Pharma, INC. | $12.20 | 2021 | |
| Medtronic, INC. | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.